PMID- 26923459 OWN - NLM STAT- MEDLINE DCOM- 20161230 LR - 20181113 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 6 DP - 2016 Feb 29 TI - In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity. PG - 22198 LID - 10.1038/srep22198 [doi] LID - 22198 AB - Matrix metalloproteinase-2 (MMP2) is important in tumorigenesis, angiogenesis and tumor invasion. In this study, we investigated if the Cy5-tagged small immuno protein targeting the catalytic domain of human MMP2 (aMMP2-SIP) detects MMP2 in tumors non-invasively. For this purpose, we generated MMP2 expressing (empty vector EV) and knock-down (KD) HT1080, U373 and U87 cells, which were injected subcutaneously in the lateral flank of NMRI-nu mice. Optical imaging (Optix MX2) performed at 0.5, 2, 4, 8, 24 and 48 hour post injection (h.p.i.) of Cy5 tagged aMMP2-SIP, indicated significantly lower tumor to background ratios at both 24 (P = 0.0090) and 48 h.p.i. (P < 0.0001) for the U87 MMP2-KD compared to control tumors. No differences were found for HT1080 and U373 models. U87 MMP2-KD tumors had significantly lower MMP2 activity (P < 0.0001) than EV tumors as determined by gelatin zymography in tumor sections and lysates, while no differences were observed between EV and MMP2-KD in HT1080 and U373. In line with these data, only U87 MMP2-KD tumors had a reduced tumor growth compared to control tumors (P = 0.0053). aMMP2-SIP uptake correlates with MMP2 activity and might therefore be a potential non-invasive imaging biomarker for the evaluation of MMP2 activity in tumors. FAU - Panth, Kranthi Marella AU - Panth KM AD - Department of Radiation Oncology (MAASTRO), GROW, MUMC, Maastricht, the Netherlands. FAU - van den Beucken, Twan AU - van den Beucken T AD - Department of Radiation Oncology (MAASTRO), GROW, MUMC, Maastricht, the Netherlands. AD - Department of Toxicogenomics, GROW, MUMC, Maastricht, the Netherlands. FAU - Biemans, Rianne AU - Biemans R AD - Department of Radiation Oncology (MAASTRO), GROW, MUMC, Maastricht, the Netherlands. FAU - Lieuwes, Natasja G AU - Lieuwes NG AD - Department of Radiation Oncology (MAASTRO), GROW, MUMC, Maastricht, the Netherlands. FAU - Weber, Marcel AU - Weber M AD - Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland. FAU - Losen, Mario AU - Losen M AD - Department of Psychology and Neuropsychology, MHeNS, MUMC, Maastricht, the Netherlands. FAU - Yaromina, Ala AU - Yaromina A AD - Department of Radiation Oncology (MAASTRO), GROW, MUMC, Maastricht, the Netherlands. FAU - Dubois, Ludwig J AU - Dubois LJ AD - Department of Radiation Oncology (MAASTRO), GROW, MUMC, Maastricht, the Netherlands. FAU - Lambin, Philippe AU - Lambin P AD - Department of Radiation Oncology (MAASTRO), GROW, MUMC, Maastricht, the Netherlands. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160229 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Antibodies) RN - 0 (Integrin alphaVbeta3) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) SB - IM MH - Animals MH - *Antibodies/immunology MH - Cell Line, Tumor MH - Disease Models, Animal MH - Enzyme Activation MH - Gene Expression MH - Heterografts MH - Integrin alphaVbeta3/genetics/metabolism MH - Matrix Metalloproteinase 2/genetics/immunology/*metabolism MH - Mice MH - Mice, Knockout MH - Molecular Imaging/*methods MH - Neoplasms/diagnosis/genetics/*metabolism MH - Optical Imaging/*methods MH - Reproducibility of Results MH - Tumor Microenvironment PMC - PMC4770595 EDAT- 2016/03/01 06:00 MHDA- 2016/12/31 06:00 PMCR- 2016/02/29 CRDT- 2016/03/01 06:00 PHST- 2015/10/22 00:00 [received] PHST- 2016/02/09 00:00 [accepted] PHST- 2016/03/01 06:00 [entrez] PHST- 2016/03/01 06:00 [pubmed] PHST- 2016/12/31 06:00 [medline] PHST- 2016/02/29 00:00 [pmc-release] AID - srep22198 [pii] AID - 10.1038/srep22198 [doi] PST - epublish SO - Sci Rep. 2016 Feb 29;6:22198. doi: 10.1038/srep22198.